Prevalence of Hepatitis B and C Infections and Associated Risk Factors in Pars Cohort Study, Southern Iran.
Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
Iran
Prevalence
Risk factors
Treatment
Journal
Middle East journal of digestive diseases
ISSN: 2008-5230
Titre abrégé: Middle East J Dig Dis
Pays: Iran
ID NLM: 101535395
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
28
09
2020
accepted:
03
03
2021
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
30
10
2021
Statut:
ppublish
Résumé
BACKGROUND Hepatitis B and C virus (HBV and HCV) infections rank among the most frequent infectious diseases with a rising worldwide burden. However, their epidemiology and risk factors are understudied in many regions, including Iran. METHODS This study was conducted as part of the Pars Cohort Study (PCS) in Valashahr district, Fars province (2012-2014). Participants received venipuncture for HBsAg and HCV antibody, followed by Polymerase Chain Reaction (PCR) testing. All infected people and their comparison groups completed a risk assessment questionnaire. RESULTS Overall, 9,269 people participated in the study; the majority were women and of Fars ethnicity. Prevalence of HBsAg and HCV antibody was 2.3% (n = 215) and 0.3% (n = 26), from whom 23% (n = 47) and 13% (n = 3) had indications for treatment, respectively. During follow-up, among HBsAg-positive individuals who were not on treatment, 62% tested negative for HBsAg, and in 2% HBV DNA had risen to treatment levels. Risk factors for HBV infection were illiteracy [OR = 3.43, 95% CI = 1.1, 10.3], and Turk ethnicity compared to Fars [OR = 1.58, 95% CI = 1.1, 2.3]. History of blood transfusion [OR = 2.00, 95% CI = 1.1, 3.5] and history of drug use [OR = 2.85, 95% CI = 1.1, 7.4] were associated with HCV infection, after adjustment. CONCLUSION Further epidemiological studies are needed to identify at-risk populations in different regions. Preventive interventions, including educational programs and transfusion safety strategies, are crucial for reducing the hepatitis burden.
Identifiants
pubmed: 34712446
doi: 10.34172/mejdd.2021.211
pmc: PMC8531928
doi:
Types de publication
Journal Article
Langues
eng
Pagination
95-102Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
CONFLICT OF INTEREST The authors declare no conflict of interest related to this work.
Références
Lancet. 2015 Oct 17;386(10003):1546-55
pubmed: 26231459
Int J Drug Policy. 2019 Oct;72:99-105
pubmed: 31303262
Harm Reduct J. 2020 Aug 14;17(1):56
pubmed: 32795371
BMC Public Health. 2018 May 22;18(1):649
pubmed: 29789002
World J Gastroenterol. 2017 Jan 7;23(1):151-166
pubmed: 28104991
World J Clin Cases. 2018 Nov 6;6(13):589-599
pubmed: 30430114
Caspian J Intern Med. 2019 Summer;10(3):326-331
pubmed: 31558996
J Clin Diagn Res. 2015 Oct;9(10):LC13-7
pubmed: 26557546
Hepat Mon. 2016 Apr 26;16(4):e35577
pubmed: 27257428
Hepat Mon. 2015 Feb 06;15(2):e24734
pubmed: 25788957
Int J Public Health. 2017 Apr;62(3):397-406
pubmed: 27349480
PLoS One. 2019 Jan 15;14(1):e0198449
pubmed: 30645598
Vaccine. 2012 Mar 9;30(12):2212-9
pubmed: 22273662
Sci Rep. 2018 Jan 9;8(1):150
pubmed: 29317673
PLoS Med. 2014 Jun 17;11(6):e1001663
pubmed: 24937136
Hepatology. 2003 Mar;37(3):590-9
pubmed: 12601357
J Gastroenterol Hepatol. 1997 Nov;12(11):752-7
pubmed: 9430042
Lancet. 2016 Sep 10;388(10049):1081-1088
pubmed: 27394647
Arch Iran Med. 2015 Sep;18(9):562-6
pubmed: 26317595
J Res Med Sci. 2018 Oct 26;23:87
pubmed: 30505325
Arch Iran Med. 2018 Oct 01;21(10):436-442
pubmed: 30415551
J Immigr Minor Health. 2017 Aug;19(4):987-990
pubmed: 28035646
Harm Reduct J. 2020 Oct 20;17(1):80
pubmed: 33081794
Middle East J Dig Dis. 2016 Jan;8(1):5-18
pubmed: 26933476
Hepat Mon. 2016 Aug 14;16(9):e36452
pubmed: 27822260
Clin Gastroenterol Hepatol. 2004 Jun;2(6):456-8
pubmed: 15181611